Galectin Therapeutics Inc (NASDAQ: GALT) is developing medical therapies for liver fibrosis and cancer by targeting galectin proteins
Atlanta, Georgia
Joined March 2013
- Tweets1.2K
- Following168
- Followers728
- Likes241
Pinned Tweet
Nearly 2M Americans will develop cirrhosis from fatty liver disease – and there’s still no treatment. Joel Lewis joined “The Tape” show with @ptsweeney and @mg_miller to discuss drug aimed at helping patients survive without a liver transplant. bloomberg.com/news/audio/202…
2
2
1,064
UPDATE: Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 investor.galectintherapeutic…
3
834
We are excited to announce we will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases @AASLDtweets next week.
Read more: investor.galectintherapeutic…
1
754
Nearly 2M Americans will develop cirrhosis from fatty liver disease – and there’s still no treatment.
Joel Lewis joined “The Tape” show with @ptsweeney and @mg_miller to discuss drug aimed at helping patients survive without a liver transplant. bloomberg.com/news/audio/202…
2
371
Galectin will share five scientific presentations at The Liver Meeting 2022, hosted by @AASLDtweets this weekend. Get a preview of the abstracts at the link below. We look forward to seeing everyone attending AASLD. investor.galectintherapeutic…
2
On 10/17/22, Galectin will present in the H.C. Wainwright 6th Annual NASH Investor Conference.
Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will deliver a corporate presentation at the conference. investor.galectintherapeutic…
1
A live webcast of the discussion will be available at the link below: journey.ct.events/view/8b19c…
NEW: Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer
investor.galectintherapeutic…
1
3
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024
finance.yahoo.com/news/galec…
Currently, there is no treatment for fatty liver disease other than diet & exercise, which are only somewhat effective in early stages of the disease. Which is why our clinical trial to develop a treatment for the late stages of this disease is so crucial.axios.com/2022/06/08/latinos…
With a staggering 80 to 100 million Americans affected, our clinical study exploring a new treatment for the late stages of the disease that can lead to liver failure is an important step forward.
With increasing frequency, doctors have seen ultrasound results demonstrating “fatty liver” in patients. news.yahoo.com/fatty-liver-d…
With increasing frequency, doctors have seen ultrasound results demonstrating “fatty liver” in patients. news.yahoo.com/fatty-liver-d…
Curious to know the process of GALT’s Phase 2b/3 NAVIGATE Study? Here’s a thread with what you need to know 👇
1
4
👩⚕️ After an additional 18-months of treatment, doctors will perform another endoscopy
📊 Finally, the results of both phases of the trial will be analyzed to determine if belapectin should become an approved therapy for NASH cirrhosis
1
1
Interested in participating in the trial? Click here to see if you qualify and to learn more bit.ly/3IdXno0
NASH #cirrhosis will soon become the number one reason for #liver transplants. $GALT is conducting research to change that in its NAVIGATE Study, the only adaptive Phase 2b/3 clinical trial focused on #NASH cirrhosis. Learn more here: navigatenash.com/